



Published by the
N.J. Dept. of Human Services,
Div. of Medical Assistance & Health Services
& the N.J. Dept. of Health & Senior Services
Div. of Consumer Support

Newsletter

Volume 9 No. 9

February 1999

TO: Providers of Pharmaceutical Services - **For Action**
Health Maintenance Organizations - **For Information Only**

SUBJECT: Notification of Medicaid Drug Federal Upper Limit (FUL) Changes -
ACTION

EFFECTIVE: December 30, 1998

ACTION: As a result of changes in the marketplace, generic versions of the following drug products are **no longer** available at or below the Medicaid Drug Federal Upper Limit prices. Consequently, the Medicaid FUL is suspended for the following products:

GENERIC NAME

COMMONLY KNOWN BRAND NAME

Amitriptyline Hydrochloride

Elavil

10 mg, Tablet, Oral 100

25 mg, Tablet, Oral 100

50 mg, Tablet, Oral 100

75 mg, Tablet, Oral 100

100 mg, Tablet, Oral 100

150 mg, Tablet, Oral 100

Amitriptyline Hydrochloride; Perphenazine

Triavil

10 mg; 2 mg, Tablet, Oral 100

10 mg; 4 mg, Tablet, Oral 100

25 mg; 2 mg, Tablet, Oral 100

25 mg; 4 mg, Tablet, Oral 100

Bethanechol Chloride

Urecholine

10 mg, Tablet, Oral 100

50 mg, Tablet, Oral 100

GENERIC NAME**COMMONLY KNOWN BRAND NAME**

Carisoprodol
350 mg, Tablet, Oral 100

Soma

Oxazepam
10 mg, Capsule, Oral 100
15 mg, Capsule, Oral 100
30 mg, Capsule, Oral 100

Serax

Note: This information is also available on the HCFA Internet website @ www.hcfa.gov/medicaid/drug10.htm.

Reimbursement by the New Jersey Medicaid program (Medicaid), NJ KidCare program, Pharmaceutical Assistance to the Aged and Disabled (PAAD) program, General Assistance (GA) program, and Cystic Fibrosis Drug (CFD) program for pharmaceutical claims for the above drugs will be based **on the lower of a drug's Average Wholesale Price (AWP) minus 10% discount, plus a dispensing fee (if applicable); or a provider's Usual and Customary Charge.**

If you have any questions regarding this Newsletter, please do not hesitate to contact the Chief, Pharmaceutical Services, DMAHS, at (609) 588-2724, or the Unisys Pharmacy Consultant at (609) 588-6039.

If you have any questions regarding PAAD and CFD, please contact Kathleen Mason, Director of PAAD, DHSS, at (609) 588-7032.

**RETAIN THIS NEWSLETTER NUMERICALLY BEHIND THE NEWSLETTER TAB
(BLUE TAB MARKED "5")**